Copyright
©The Author(s) 2019.
World J Diabetes. Mar 15, 2019; 10(3): 189-199
Published online Mar 15, 2019. doi: 10.4239/wjd.v10.i3.189
Published online Mar 15, 2019. doi: 10.4239/wjd.v10.i3.189
Table 1 Demographic data: Participants with type 1 diabetes and their first-degree relatives n (%)
Demographics | T1D only (n = 280) | T1D + CD (n = 22) | FDR only (n = 689) | FDR +CDA (n = 36) |
White | 249 (88.9) | 22 (100) | 629 (91.3) | 35 (97.2) |
Not hispanic | 188 (67.1) | 15 (68.2) | 451 (65.5) | 27 (75.0) |
Female | 178 (63.6) | 17 (77.3) | 409 (59.4) | 26 (72.2) |
Age at screening (yr), median (range) | 19 (2-72) | 14.5 (7-43) | 40 (1-74) | 39.5 (3-55) |
Age at diagnosis of T1D (yr), median (range) | 10 (0.1-64) | 6.5 (1-21) | ||
Presence of gastrointestinal symptoms (GI sx) | 113 (40.5) | 6 (27.3) | 216 (31.4) | 13 (36.1) |
Presence of extraintestinal symptoms (Ex sx) | 78 (27.9) | 3 (13.6) | 176 (25.5) | 7 (19.4) |
Both GI and Ex symptoms | 56 (20) | 3 (13.6) | 98 (14.2) | 4 (11.1) |
Asymptomatic | 144 (51.6) | 16 (72.7) | 394 (57.3) | 20 (55.6) |
Human leukocyte antigen (HLA) genotype | ||||
DR3-DQ2 | 49 (18) | 2 (9.1) | 148 (21.8) | 10 (28.6) |
DR3-DQ2 homozygote | 18 (6.6) | 3 (13.6) | 25 (3.7) | 3 (8.6) |
DR7-DQ2 | 12 (4.4) | 1 (4.6) | 41 (6.1) | 2 (5.7) |
DR7-DQ2 homozygote | 2 (0.7) | 0 (0) | 13 (1.9) | 0 (0) |
DR3/DR7-DQ2 homozygote | 1 (0.37) | 0 (0) | 20 3.0) | 3 (8.6) |
DR4-DQ8 | 83 (30.5) | 5 (22.7) | 205 (30.2) | 10 (28.6) |
DR3-DQ2/DR4-DQ8 | 70 (25.7) | 7 (31.8) | 50 (7.4) | 6 (17.1) |
DR7-DQ2/DR4-DQ8 | 6 (2.2) | 4 (18.2) | 33 (4.9) | 0 (0) |
DQ2/DQ8 negative | 31 (11.4) | 0 (0) | 142 (20.9) | 1 (2.9) |
Haptoglobin genotype (HP) (Zonulin) | ||||
HP 1-1 | 46 (16.4) | 2 (9.1) | 120 (17.4) | 8 (22.2) |
HP 2-1 | 118 (42.1) | 10 (45.5) | 278 (40.4) | 21 (58.3) |
HP 2-2 | 116 (41.4) | 10 (45.5) | 290 (42.2) | 7 (19.4) |
Any HP2 | 234 (83.6) | 20 (90.9) | 568 (82.6) | 28 (77.7) |
Table 2 Cohort prevalence of celiac disease and celiac disease autoimmunity
n | CD | CDA | CD at screening | CDA at screening | CDA prevalence estimation | |
Type 1 diabetes | 302 | 8 (2.7) | 3 (1.0) | 8 (2.5) | 3 (0.7) | 22 (7.3) |
First-degree relative | 725 | 9 (1.2) | 4 (0.6) | 18 (2.7) | 5 (1.0) | 36 (5.0) |
Table 3 Univariate and multiple regression models: Factors related to celiac disease autoimmunity in participants with type 1 diabetes
Estimate | Se | Lower limit | Upper limit | Z stat | P-value | |
Univariate Model (exchangeable correlation) | ||||||
Female | 0.6562 | 0.5151 | -0.3534 | 1.6659 | 1.27 | 0.2027 |
Age | -0.0314 | 0.0152 | -0.0611 | -0.0017 | -2.07 | 0.0383A |
Onset of T1D | -0.0658 | 0.0342 | -0.1329 | 0.0013 | -1.92 | 0.0546 |
Gastrointestinal (GI) symptoms | -0.5812 | 0.491 | -1.5435 | 0.3811 | -1.18 | 0.2365 |
Extraintestinal (EX) symptoms | -0.9204 | 0.6391 | -2.1731 | 0.3323 | -1.44 | 0.1498 |
Both GI and EX symptoms | -0.4724 | 0.6385 | -1.7239 | 0.7791 | -0.74 | 0.4594 |
No GI or EX symptoms | 0.9074 | 0.4931 | -0.059 | 1.8737 | 1.84 | 0.0657 |
Human Leukocyte Antigen (HLA) DQ2-DR3 Heterozygous | -0.7402 | 0.7571 | -2.2241 | 0.7437 | -0.98 | 0.3282 |
HLA DQ2-DR3 Homozygous | 0.7843 | 0.67 | -0.5332 | 2.1019 | 1.17 | 0.2433 |
HLA DQ2-DR7 Heterozygous | 0.028 | 1.0649 | -2.0592 | 2.1152 | 0.03 | 0.979 |
HLA DQ8 | -0.3975 | 0.5234 | -1.4233 | 0.6283 | -0.76 | 0.4475 |
HLA DQ2-DR3/DQ8 | 0.2767 | 0.4814 | -0.6668 | 1.2203 | 0.57 | 0.5654 |
HLA DQ2-DR7/DQ8 | 2.4851 | 0.6507 | 1.2098 | 3.7604 | 3.82 | 0.0001B |
HLA DQ2 Heterozygous | -0.575 | 0.6367 | -1.823 | 0.6729 | -0.9 | 0.3665 |
HLA DQ2 Homozygous | 0.6192 | 0.666 | -0.6862 | 1.9246 | 0.93 | 0.3525 |
Haptoglobin genotype (HP) 1-1 | -0.6932 | 0.7671 | -2.1967 | 0.8104 | -0.9 | 0.3662 |
HP 2-1 | 0.1539 | 0.4414 | -0.7112 | 1.0191 | 0.35 | 0.7273 |
HP 2-2 | 0.1525 | 0.4422 | -0.7141 | 1.0192 | 0.34 | 0.7301 |
Any HP2 | 0.693 | 0.767 | -0.81 | 2.197 | 0.9 | 0.366 |
First degree relative (FDR) with celiac disease (CD) | 1.4091 | 0.6188 | 0.1962 | 2.622 | 2.28 | 0.0228C |
FDR with Type 1 diabetes (T1D) | 0.0724 | 0.557 | -1.0193 | 1.1641 | 0.13 | 0.8966 |
FDR with thyroid disease | 0.7839 | 0.4619 | -0.1215 | 1.6892 | 1.7 | 0.0897 |
FDR with other autoimmune disease | 1.1634 | 0.4432 | 0.2947 | 2.0321 | 2.62 | 0.0087D |
CD in another relative | 0.4136 | 0.6598 | -0.8796 | 1.7068 | 0.63 | 0.5307 |
Multiple Regression Model (independence working correlation) | ||||||
Intercept | -3.3213 | 0.927 | -5.1383 | -1.5043 | -3.58 | 0.0003 |
Age | -0.0121 | 0.019 | -0.0494 | 0.0252 | -0.64 | 0.5246 |
Onset of T1D | -0.0396 | 0.0425 | -0.1229 | 0.0436 | -0.93 | 0.3509 |
DQ2-DR7/DQ8 | 2.4131 | 0.8401 | 0.7666 | 4.0596 | 2.87 | 0.0041E |
No GI or EX symptoms | 1.1905 | 0.6566 | -0.0963 | 2.4774 | 1.81 | 0.0698 |
FDR with CD | 0.6927 | 1.3443 | -1.9421 | 3.3274 | 0.52 | 0.6064 |
FDR with thyroid disease | -0.8976 | 1.6214 | -4.0756 | 2.2804 | -0.55 | 0.5799 |
FDR with other autoimmune disease | 1.9765 | 1.7861 | -1.5241 | 5.4771 | 1.11 | 0.2685 |
Table 4 Univariate and multiple regression models: Factors related to celiac disease autoimmunity in first degree relatives of participants with type 1 diabetes
Estimate | Se | Lower limit | Upper limit | Z stat | P-value | |
Univariate model (exchangeable correlation) | ||||||
White | 1.26 | 0.88 | -0.47 | 2.98 | 1.43 | 0.154 |
Female | 0.5433 | 0.3674 | -0.1768 | 1.2635 | 1.48 | 0.1392 |
Age | -0.0046 | 0.0097 | -0.0236 | 0.0144 | -0.47 | 0.6355 |
Gastrointestinal (GI) symptoms | 0.2551 | 0.3395 | -0.4103 | 0.9206 | 0.75 | 0.4524 |
Extraintestinal (EX) symptoms | -0.3748 | 0.4596 | -1.2756 | 0.526 | -0.82 | 0.4148 |
Both GI and EX symptoms | -0.2715 | 0.5305 | -1.3113 | 0.7682 | -0.51 | 0.6087 |
No GI or EX symptoms | -0.085 | 0.3419 | -0.7551 | 0.5851 | -0.25 | 0.8036 |
Human Leukocyte Antigen (HLA) DQ2-DR3 Heterozygous | 0.4255 | 0.383 | -0.3251 | 1.1761 | 1.11 | 0.2666 |
HLA DQ2-DR3 Homozygous | 0.8042 | 0.7654 | -0.696 | 2.304 | 1.05 | 0.2934 |
HLA DQ2-DR7 Heterozygous | -0.0376 | 0.6636 | -1.3382 | 1.263 | -0.06 | 0.9548 |
HLA DQ2-DR3/DR7 Homozygous | 1.02 | 0.715 | -0.381 | 2.42 | 1.43 | 0.153 |
HLA DQ8 | -0.0981 | 0.4058 | -0.8934 | 0.6972 | -0.24 | 0.809 |
HLA DQ2-DR3/DQ8 | 0.9272 | 0.472 | 0.0021 | 1.8523 | 1.96 | 0.0495A |
HLA DQ2/DQ8 Negative | -2.1836 | 1.0232 | -4.1891 | -0.1781 | -2.13 | 0.0328B |
HLA DQ2 Heterozygous | 0.3561 | 0.388 | -0.4043 | 1.1166 | 0.92 | 0.3586 |
HLA DQ2 Homozygous | 0.6842 | 0.5435 | -0.3811 | 1.7495 | 1.26 | 0.2081 |
Haptoglobin genotype (HP) 1-1 | 0.2901 | 0.4341 | -0.5607 | 1.1409 | 0.67 | 0.5039 |
HP 2-1 | 0.6823 | 0.3429 | 0.0103 | 1.3544 | 1.99 | 0.0466C |
HP 2-2 | -1.0763 | 0.4252 | -1.9096 | -0.2429 | -2.53 | 0.0114D |
Any HP2 | -0.29 | 0.434 | -1.141 | 0.561 | -0.67 | 0.503 |
First degree relative (FDR) with CDceliac disease (CD) | 1.6768 | 0.3809 | 0.9303 | 2.4233 | 4.4 | <.0001E |
FDR with thyroid disease | -0.503 | 0.4849 | -1.4533 | 0.4473 | -1.04 | 0.2995 |
FDR with other autoimmune disease | 0.6817 | 0.3606 | -0.025 | 1.3884 | 1.89 | 0.0587 |
CD in other relative | 0.5217 | 0.7115 | -0.8728 | 1.9161 | 0.73 | 0.4634 |
Multiple regression model (independence working correlation) | ||||||
Intercept | -2.8829 | 0.404 | -3.6746 | -2.0912 | -7.14 | < 0.0001 |
HLA DQ2-DR3/DQ8 | 0.9407 | 0.5381 | -0.1139 | 1.9953 | 1.75 | 0.0804 |
HLA DQ2/DQ8 Negative | -1.9348 | 1.0275 | -3.9487 | 0.0791 | -1.88 | 0.0597 |
HP 2-1 | 0.0804 | 0.4492 | -0.8001 | 0.9609 | 0.18 | 0.858 |
HP 2-2 | -1.0149 | 0.563 | -2.1185 | 0.0886 | -1.8 | 0.0715 |
FDR with CD | 2.3635 | 0.7576 | 0.8787 | 3.8483 | 3.12 | 0.0018F |
FDR with other autoimmune disease | -0.8269 | 0.7245 | -2.2468 | 0.5932 | -1.14 | 0.2538 |
- Citation: Leonard MM, Camhi S, Kenyon V, Betensky RA, Sturgeon C, Yan S, Fasano A. Targeted genotyping for the prediction of celiac disease autoimmunity development in patients with type 1 diabetes and their family members. World J Diabetes 2019; 10(3): 189-199
- URL: https://www.wjgnet.com/1948-9358/full/v10/i3/189.htm
- DOI: https://dx.doi.org/10.4239/wjd.v10.i3.189